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2:00 
~ A  PrOSl~¢tlv~ 1Vial on the Efft~ts of ko~a~n on the 
Oegrtm of Mlt~l Re0urgltatton 
KS, Ogj~rdm. ME_- S~lrplno, J B ~awaf0 M~y~ Chn~: an# Ma)'~ 
FoundatiOn, Rochester, Afm#esot.~. USA 
V~so~lplto~ h~lve ~n ~ ¢limcalty in p~ w~th m~tral fegurgitatmn (MR), 
t~f  e f i~cy  in ~K~ing  volume m,'edoad caused by MR is not quantita, 
l~ely ~nted  In 11 p+ospect~ p~tO! In°l, 29 pts (23 men, age 68 • 14) 
u~n!  a quantttatwe ¢~ngmm at baseline an# tour hours ~fter 
mg ~t lan  o~ally "t~ne regurg~tan! ~ume (RVOl) and effectwe regurgt- 
lant onfK~ (ERe) were qu~nltt~l using two me~ (flow c~rgence  and 
quantitative Doppter) Measuvement~ in~l~ indexed left ventncutar end. 
0kastol~ (EDVI) and ert~systol~; vokm~s (ESVI), ejection fractmn (EF) and 
mean ~ ~sut ,  e (MBP) .  In 24 pts+ the ecP, D( ;a~ram was repeated 
after continued oral k~sartan ft'mral~ 50 mg QD for 30 z 13 days The effects 
ul ~Jsanan are !~uiat~o b~=low 
Ba~el+ne 4 hOurS P' I rnanth P' 
P.~PlmmHgp 101 ~ 11 91 ~ 11 - 00001 93 ; 7 O000r 
ERe tram2) 43 : r? 36 : 16 0 0901 37 : 18 0 0001 
(ccl 75 .~ 29 64 ~ 27 00001 6~ : 29 0 0001 
EOVtlm~'m2) 128 ,. ~ 11~ : r8 - 0000~ 117 t 16 00029 
ESVI !mira2} 48 ~ 2~ 4~ ~ 23 0034 40 20 014 
ConctusK~s. We cortcl~%=d that treatment Of n~lral regurgitation using 
the anc~otens+n II bk~ker to°art°n+ 1) has fa~orab{e ffects wdh a s~gr~fi- 
cam ~educt~on of reg~g~tant volume, mgur~tant entice and felt venb'lcuiar 
rem.JcleSng: 2) these favorable effects appear to persist v~ trine, 3) are ot 
mrYJerate magndu~e, suggeshng that 4) the evaluation of ~ clinical effects 
of the medication m a controlled that ts warranted 
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i Long-term Therapy W'dh Enalapril in Asymptomatic 
Patients W'dh Moderate to Severe Chronic Mitral 
Regurgitation 
AGoda, T Go~a. A. KastratL S O~rko Umvers~ty Ho~tat Cen~e~ Dept at 
Car~. .  T#rana. Albania 
Background: Vaseditators acutely reduce regurg~tant volume and i,"r~ro've 
left ventncuta~ (LV) performance in mdral regurgdation (MR), but mere data 
are necessa W about their long-term efficacy 
Methods: To assess the Iong term effect of ACE inhibition in °symptomatic 
patients (or) ~th  rnodorste 1o severe MR we compared) echocard~ographrc 
left ventncular (LV) pedormance in 30 pt betore and after 6 months After 
randornisation 15 pt were aflocated to enalap.I (E) therapy (24 : 7 rag/day) 
and 15 pt served as control (C). 
Results: There were no d~fferences in baseline Echo measurements ot 
LV diameters, volumes, mass and mean wail stress (MWS) between E and 
C groups. After 6 months pt receiving E had a reduction in end-diastolic 
diameter (EDD) (from 63.9 : 6.7 to 605 ~ 4.1 ram, p = 002) and volume 
(EDVI) (from 115.9 : 21.4 to 102.9 ~ 13.6 mt/rr~, p = 002). LV mass (from 
176.5 ;: 41.0 to 151 4 *. 226 g/n~, p .  0.02) and MWS (from 2530 = 361 
to 223.6 ± 26.8 kdyne/cm ~. p ~ 001). End-systo,c diameter (ESD). volume 
(ESVI) and EF were not altered. In C group EDD. ESD. EDVI. ESVl. El:. 
mass and MWS did not change significantly after 6 months. In addition, there 
was a clear difference between E and C group in EDD (60.5 = 4.1 vs 65.3 : 
7 1 mm, p = 0.03), ESD (37.7 -. 4.1 vs 40.5 +. 4.2 ram, p = 0.07). EDVl (102.9 
13.6vs 1179 *. 28.2ml/m 2 .p -  0.05), mass (1504 : 22.6vs168.3 : 
29.5 g/m z. p - 0.05) and MWS (223.6 : 26.8 vs 257 3 ~. 31 0 kdyne/cm 2. p 
• 0.01) after 6 months. 
Conclusions: Long term therapy with enalapril in asymptomalic pt with 
moderate to severe chronic MR reduces LV size and mass suggesting the 
potential to delay timing f0r mttral valve surgery. 
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Improve Homodynamlcs and Contrlctlle Function in 
Experimental Mitral Regurgitation 
M Ham~wakl, G. 0#Ffeyle, BA  C~lrat~llo. ~ t  ~?y '  of Sou/h 
Carohn~ ~lnd VAMC, Ct~ge~ton, ~l~fh CaroIdna, USA 
Altho,~g~ well established in t110 therapy el ¢o~3gestive t~saR failure, t l~ fete 
0t ACE inhibitor° and beta.bk~kers in milra! regurgitation (MR) reefs+n° 
¢onttover~ttal Accordingly, we ~1~t~11he sequential ~ Of fismop~! (k) 
~ ,~teno(oI (A) (k * A) on 7 dO0° wdh ~evem lett vent~'t~lar (LV) dysftmctmn 
due Io 3 months 0t MR, 
B~e~!i~ 3moMR 6rtl~ MR • L 9 r r~MR*L*A  
LV n",~rs'~OW Ig~g ) 447 ~ 0~5 5fit ~ 0,33 56(}=043 61.3,041' 
RF(%) 600~t5  652141 624~2~ ~4~'41  
PCW (mmHg) 9 f l~13 154~11 1~1~12 (~1~14 = 
K m~e~ 348~ 017 2,51 : 015 ~ 291 ~0t6 33~ ~019 ~ 
"p 005 ~s baseh~e ~p 005 vs .3 me. BW : ~ we+gf~t RF = ~eg,.~g~tant hactmn 
PCW = pulmonary capdtanf wedge pt'eseufe. K = end eyslo+~C stlffr, ess 
We conclude that while there was a tendency for ~mprovemPnt in heine. 
d~/nam~'s w~th L only the cerebra°Iron o! L + A improved hemodynam~ca nd 
normalized contraCtility 
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~ Eff~-'t= of Inhaled N~!c Oxide in Pa~ts  With 
Severe Mitral Steno,ds and Normal ~ Vmttricular 
Function 
PD. Mahoney, E Lob. LR. Biffs, CW Hanson. H C Hen'mann Unmers~Iy 
ot Pennsylvania Medical Center, Phdadetph~a. Pennsylvama, USA 
M+trat stenos~s is asseoated w~th n~_~rea sod left atrial pressure and pulmonary 
hyperlens~on in the soiling Of nomlal left vonlncular function The hemody- 
nam~c effects ot inhaled nitric 0xl¢~ (NO), a selective pulmonary vasodilator, 
in n~tral steno~s are unknown Nit, le women (mean age 61 ± 7 years) wr~ 
se~.,ere rl~eumat~c n~tral stone°is in'man valve area (MVA) of t .1 ~ 0.2 cm ~ ) 
and normal LV function underwent right and left (vm Irans~eplal approach) 
heart cattteter~at~on: measurerrm.nts were made at baseline, and after tubal- 
mg NO (80 ppm) for 10 minutes (mean _+ SD: " = p ~ 0 05: 
Base,he Nffnc O~l}de 
AO meanimmHg, 96 : tt ~J6 : 13 
LVEDP (mmHg! 15 : 4 15 : 5 
L.A~ mean ~mrnt~g) 26 : 3 27 ~ 5 
PA SVsrQlEImmHgi 62 13 54 : +4" 
CO tF~Ck tm-~) 4 2 : 1 0 4 3 : 12 
SVFI~W~Ui 221 : 70  215  : 68 
PVR |W~ U) 35 ~ 2 6 2 I : I 4" 
In 6 patrents who underwent successful balloon vaNuloplasty, MVA in- 
creased from 1 0 ~ 0 1 to 1 6 -* 0.3 crr~ with a d~ase  in LA pressure 126 
.- 2 to 19 :: 4 mmHg. p ~ 0.05) and PA systolic pressure (55 ± 3 to 44 
7 rnmHg, p < 005)  The CO (4.3 ~ 1 0 ~mtn to 42  I/rain. p =NS) and PVR 
were unchenged (30 WU to 28  WU. p =NS). 
Conclusions 1) NO reduced PVR in patients with mitral slenosrs and 
normal LV funCtion by decreasing PA pressure without altenng LA pressure 
or CO. Thvs differs from previous findings m patients with LV dysfunction rn 
whom NO reduced PVR sorely by increasing pulmonary wL'~ge pressure. 2) 
PVR was unchanged immediately after valvuloplasty, des]0de Eqndence that 
+t ts no( lixed as shown by the vascular reaCtw~ty w~th NO This suggests a 
need for chronic adaptation tO the reduction in LA pressure 
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~ Diastolic Function in the Progression From Acute to 
' Chronic MR 
P Oagum'. G R Green'. GT  Daughters I1:. NB  Ingels Jr : ,  KL  Yun ~ .
D.C. Miller ~ 'Stanford Unwerstt~ Stanford, CA. USA: :Pale Alto Medrcal 
Foundation. Pale AIto, CA, USA 
Background: The change in LV diastolic function dunng the prOgreSsion from 
acute to chronic MR is unclear. 
Methods: Fifteen dogs unden,'~ent placement of 20 LV myocardial markers 
MR was created by punctunng the postenor leaflet with a Cope biopsy 
needle. Biplane videofluoroscopic studies, performed at 1 week (acute MR) 
and 3 months (chronic MR). were used to assess LV volta'no and wall 
stress. Diastolic funCtion was assessed by the maximum time denvatn/e 
and time constant of iscvolumic Dt~ssu,"e dec~y (r. -dP,'dt). time constant of 
